About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

NCT00090584·9 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Carelon Research

With

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Age

21–any

Sex

FEMALE

Healthy volunteers

Accepted

You may be eligible if

Inclusion:
Female
Urge predominant incontinence
Incontinent \> 3 mos
Available for 8 mos of followup
Exclusion:
Pregnancy or \< 6 mos post-partum
Hypersensitivity to drug (tolterodine)
Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury)
History of extensive behavior treatment

The record

StatusCompleted

PhaseNo phase

Taking part307

StartedAug 2004

UpdatedJun 17, 2013

Conditions

Urinary Incontinence (UI)

Where9

University of Alabama
Birmingham, Alabama, United States
University of California
San Diego, California, United States
Loyola University Medical Center
Maywood, Illinois, United States

Clareo Health | Behavior Enhances Drug Reduction of Incontinence (BE-DRI)